8-K: Sensus Healthcare Appoints GE HealthCare Exec Larry Biscotti to Board

Sensus Healthcare, Inc. announced the appointment of Larry Biscotti, President of Imaging for U.S. and Canada at GE HealthCare, to its Board of Directors, effective immediately.

Summary

• Sensus Healthcare, Inc. appointed Larry Biscotti as a Class I director to its Board of Directors, effective January 5, 2026.
• Mr. Biscotti's term will expire at the company's annual meeting in 2028.
• He is deemed an independent director within the meaning of Rule 5605(a)(2) of The NASDAQ Stock Market, LLC listing standards.
• Mr. Biscotti brings over 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in commercial strategy, global market expansion, and launching advanced imaging and oncology technologies.
• His prior experience includes leadership roles at GE HealthCare, Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine, and CTI Molecular Imaging.
• With this appointment, the Sensus Healthcare Board now has six directors, including four independent directors.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and respected industry veteran to the board is a strong positive for corporate governance and strategic direction, indicating a commitment to growth and innovation. No negative information was disclosed.

Positives

• Appointment of Larry Biscotti, a highly experienced executive with over 25 years in medical device and healthcare technology, to the Board of Directors.
• Mr. Biscotti's background includes leading multibillion-dollar P&Ls, introducing innovative cancer treatment technologies, building and scaling commercial teams, and expanding businesses globally through strategic partnerships and distribution agreements.
• His current role as President, Imaging for U.S. and Canada at GE HealthCare demonstrates significant industry leadership and expertise.
• The addition of an independent director strengthens corporate governance and provides valuable external perspective.
• Management views Mr. Biscotti's integrity, judgment, and commitment to patient outcomes as a strong fit for the company's culture and mission.

Future Outlook

The company aims to expand the reach of its SRT technology and execute on its long-term vision, with Mr. Biscotti expected to support Sensus Healthcare's continued growth and impact for patients and clinicians.

Management Comments

• "Larry brings to the Sensus Board a wealth of skills, value and complementary experiences. Over the course of his career, he has led multibillion-dollar P&Ls, introduced innovative cancer treatment technologies, built and scaled commercial teams and expanded businesses globally through strategic partnerships and distribution agreements." Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare.
• "His integrity, judgment and commitment to improving patient outcomes fit well with our culture and mission. I've had the privilege of working with Larry throughout my career and know firsthand the leadership and insight he brings." Joe Sardano.
• "I am honored to join the Board of Directors of Sensus Healthcare at a time when patient-centered, non-invasive treatments are becoming increasingly important for a variety of conditions." Larry Biscotti.
• "The company's commitment to innovation, clinical excellence and improving patient outcomes strongly aligns with my own personal values and professional experiences. I look forward to supporting Sensus' continued growth and impact for patients and clinicians." Larry Biscotti.

Industry Context

The appointment of a seasoned executive from GE HealthCare's imaging division highlights the increasing importance of non-invasive, patient-centered treatments and advanced imaging/oncology technologies within the medical device and healthcare technology sectors. Sensus Healthcare's focus on superficial radiotherapy (SRT) aligns with this trend, and Mr. Biscotti's extensive experience is expected to bolster their strategic positioning and global expansion efforts in a competitive market.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive due to enhanced board expertise and strategic guidance, which could lead to improved company performance and value.
• Employees: Potential for stronger leadership and strategic direction, possibly leading to new opportunities or clearer company objectives.
• Customers/Clinicians: Potential for continued innovation and expansion of effective treatment platforms (SRT technology).

Next Steps

• Determination of any committee appointments for Mr. Biscotti.
• Continued expansion of SRT technology reach.
• Execution of the company's long-term vision.

Key Dates

Keywords

Sensus Healthcare, SRTS, Board of Directors, Director Appointment, Larry Biscotti, Medical Device, Healthcare Technology, Oncology, Radiation Therapy, Corporate Governance, Independent Director, GE HealthCare